论文部分内容阅读
目的探讨沙美特罗/氟替卡松治疗慢性阻塞性肺疾病(COPD)对患者肺功能和气道炎症的影响。方法 回顾性分析2009年11月-2010年4月馆陶县人民医院收治的118例COPD患者的相关临床资料,采用沙美特罗/氟替卡松治疗的60例作为观察组,仅采用常规治疗的58例作为对照组,对两组患者肺功能和气道炎症改善情况进行比较分析。结果观察组治疗后6个月内患者的急性发作次数及住院时间均明显少于对照组,两组间差异有统计学意义(P<0.05);治疗后观察组患者的一秒率(FEV1.0%)、血清肿瘤坏死因子α(TNF-α)、转化生长因子β(TGF-β)均明显优于对照组,差异有统计学意义(P<0.05)。结论沙美特罗/氟替卡松治疗COPD疗效显著,能明显改善患者的肺功能和气道炎症情况,值得在临床推广应用。
Objective To investigate the effects of salmeterol / fluticasone on pulmonary function and airway inflammation in patients with chronic obstructive pulmonary disease (COPD). Methods The clinical data of 118 patients with COPD admitted to Guantao People’s Hospital from November 2009 to April 2010 were retrospectively analyzed. Fifty-six patients treated with salmeterol / fluticasone were selected as the observation group. As a control group, the two groups of patients with lung function and airway inflammation were compared to improve the situation. Results The number of acute attacks and hospital stay in the observation group within 6 months after treatment were significantly less than those in the control group, with significant difference between the two groups (P <0.05). The second-second rate (FEV1. 0%), serum tumor necrosis factor α (TNF-α) and transforming growth factor β (TGF-β) were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusions Salmeterol / fluticasone is effective in treating COPD, and can significantly improve pulmonary function and airway inflammation in patients. It is worthy of clinical application.